Lazard Asset Management
GYRE icon

Lazard Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Lazard Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,932
Closed -$111K – 1947
2025
Q3 		$111K Buy
+14,932
New +$113K ﹤0.01% 1676
2025
Q2 		– Sell
-833
Closed -$6K – 2387
2025
Q1 		$6K Buy
+833
New +$9.14K ﹤0.01% 2174
2023
Q1 		– Sell
-7,096
Closed -$28K – 2405
2022
Q4 		$28K Buy
7,096
+966
+16% +$3.94K ﹤0.01% 2054
2022
Q3 		$23K Buy
+6,130
New +$77.8K ﹤0.01% 2063

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lazard Asset Management's GYRE Position: Q4 2025 in Review

Lazard Asset Management sold out of Gyre Therapeutics (GYRE) in Q4 2025, closing a stake of 14,932 shares — an estimated $111K sold.

Lazard Asset Management first reported a position in GYRE in Q3 2022 and held it in 4 quarters. The position peaked at $111K in Q3 2025. 44 funds tracked by Wall St. Rank hold GYRE as of Q4 2025.

  • Lazard Asset Management reported no remaining Gyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lazard Asset Management sold 14,932 Gyre Therapeutics shares in Q4 2025, an estimated $111K.
  • Lazard Asset Management first reported a position in Gyre Therapeutics in Q3 2022 and held it in 4 quarters.
  • Lazard Asset Management's Gyre Therapeutics position peaked at $111K in Q3 2025.
  • 44 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2025.

Based on Lazard Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.